Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Amlodipine; Amlodipine, atorvastatin drug combination; Atorvastatin; Atorvastatin Calcium; Calcium

Criteria

Inclusion Criteria:

• Hypertension with three additional risks factors (for example: smoking, type 2 diabetes, family history of early heart disease, history of stroke, age over 55 (men) and 65 (women)

Exclusion Criteria:

• Subjects currently receiving a statin or stopped statin within 6 months prior to enrollment.

• Subjects with a history of myocardial infarction and subjects with coronary bypass graft or intra-coronary interventions.